Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) just unveiled an update.
MicroPort CardioFlow Medtech Corp. announced significant changes in its board of directors, with the resignation of Mr. Zhao Liang, Ms. Yan Luying, and Mr. Zhang Junjie, effective December 15, 2025. The company expressed gratitude for their contributions and confirmed there were no disagreements with the board. Dr. Brian Chang has been appointed as a non-executive director and co-chairman. Dr. Chang brings a wealth of experience in medical technology and academia, having co-founded startups and served as a lecturer at MIT. His appointment is expected to enhance the company’s strategic direction and innovation in cardiovascular technologies.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corp. is a company incorporated in the Cayman Islands, focusing on medical technology, particularly in the development of cardiovascular devices. It is part of the MicroPort Scientific Corporation group, which is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 5,283,651
Technical Sentiment Signal: Hold
Current Market Cap: HK$2.77B
See more data about 2160 stock on TipRanks’ Stock Analysis page.